The Prognostic Value of Minimal Residual Disease (MRD) after Salvage Therapy in Patients (Pts) with Relapsed or Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (ALL)

被引：0
|
作者：
Yilmaz, Musa [1 ]
Kantarjian, Hagop M. [2 ]
Ravandi, Farhad [2 ]
Jorgensen, Jeffrey L. [3 ]
Wang, Sa [3 ]
Garcia-Manero, Guillermo [2 ]
Cortes, Jorge E. [2 ]
Sasaki, Koji [2 ]
DiNardo, Courtney [2 ]
Kadia, Tapan [2 ]
Autry, Jane [2 ]
Garris, Rebecca [2 ]
Jabbour, Elias [2 ]
机构：
[1] Baylor Coll Med, Dept Hematol & Oncol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BLOOD | 2015年 / 126卷 / 23期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] A PHASE II STUDY WITH A SEQUENTIAL CLOFARABINE-CYCLOPHOSPHAMIDE COMBINATION SCHEDULE AS SALVAGE THERAPY FOR REFRACTORY AND RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (R/R ALL) IN ADULT PATIENTS
    Bassan, R.
    Fumagalli, M.
    Meloni, G.
    Audisio, E.
    Cascavilla, N.
    Paolini, S.
    Specchia, G.
    Cerqui, E.
    Mico, C.
    Fabbiano, F.
    Ronco, F.
    Scattolin, A. M.
    Perfetti, P.
    Paoloni, F.
    Vitale, A.
    Vignetti, M.
    Foa, R.
    HAEMATOLOGICA, 2017, 102 : 199 - 199
  • [32] Measurable Residual Disease (MRD)-directed therapy for Acute Lymphoblastic Leukemia (ALL)
    Nagafuji, Koji
    CANCER SCIENCE, 2025, 116 : 1797 - 1797
  • [33] Salvage therapy R-DAOx in patients with relapsed or refractory diffuse large B-CELL lymphoma
    Mappa, S.
    Rigacci, L.
    Nassi, L.
    Puccini, B.
    Alterini, R.
    Carrai, V.
    Bernardi, F.
    Bosi, A.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 532 - 532
  • [34] Phase II Study of Blinatumomab in Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Positive Measurable Residual Disease (MRD)
    Richard-Carpentier, Guillaume
    Kantarjian, Hagop M.
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Khoury, Joseph D.
    Ravandi, Farhad
    Short, Nicholas J.
    Khouri, Rita
    Takahashi, Koichi
    Ohanian, Maro
    Borthakur, Gautam M.
    Konopleva, Marina Y.
    Daver, Naval G.
    Estrov, Zeev E.
    Alvarado, Yesid
    Jain, Nitin
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Velasquez, Michelle
    Nasnas, Patrice
    O'Brien, Susan
    Jabbour, Elias
    BLOOD, 2019, 134
  • [35] Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia
    Mushtaq, Muhammad Umair
    Harrington, Alexandra M.
    Chaudhary, Sibgha Gull
    Michaelis, Laura C.
    Carlson, Karen-Sue B.
    Abedin, Sameem
    Runass, Lyndsey
    Callander, Natalie S.
    Fallon, Michael J.
    Juckett, Mark
    Hall, Aric C.
    Hematti, Peiman
    Mattison, Ryan J.
    Atallan, Ehab L.
    Murthy, Guru Subramanian Guru
    LEUKEMIA & LYMPHOMA, 2021, 62 (01) : 158 - 166
  • [36] Prognostic value of minimal residual disease in relapsed childhood acute lymphoblastic leukaemia
    Eckert, C
    Biondi, A
    Seeger, K
    Cazzaniga, G
    Hartmann, R
    Beyermann, B
    Pogodda, M
    Proba, J
    Henze, G
    LANCET, 2001, 358 (9289): : 1239 - 1241
  • [37] Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3
    Oluwole, Olalekan O.
    Ghobadi, Armin
    Cassaday, Ryan Daniel
    Park, Jae H.
    Houot, Roch
    Logan, Aaron
    Boissel, Nicolas
    Leguay, Thibaut
    Bishop, Michael Russell
    Topp, Max S.
    O'Dwyer, Kristen M.
    Baer, Maria R.
    Schiller, Gary J.
    Abedi, Mehrdad
    Minnema, Monique C.
    Stiff, Patrick J.
    Zhou, Lang
    Siddiqi, Rubina
    Khalid, Rita Damico
    Shah, Bijal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] Long-Term Outcomes after Blinatumomab Treatment: Follow-up of a Phase 2 Study in Patients (Pts) with Minimal Residual Disease (MRD) Positive B-Cell Precursor Acute Lymphoblastic Leukemia (ALL)
    Goekbuget, Nicola
    Dombret, Herve
    Bonifacio, Massimiliano
    Reichle, Albrecht
    Graux, Carlos
    Faul, Christoph
    Diedrich, Helmut
    Topp, Max S.
    Brueggemann, Monika
    Horst, Heinz A.
    Stieglmaier, Julia
    Wessels, Hendrik
    Haddad, Vincent
    Zugmaier, Gerhard
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2015, 126 (23)
  • [39] Inotuzumab ozogamicin (CMC-544) compared to chemotherapy in patients (pts) with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL): A retrospective comparison
    Faderl, Stefan
    Jain, Nitin
    O'Brien, Susan Mary
    Thomas, Deborah A.
    Ravandi, Farhad
    Jabbour, Elias
    Pierce, Sherry
    Kantarjian, Hagop M.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [40] Inotuzumab ozogamicin (IO) combined with mini-hyper-CVD as salvage therapy for patients (pts) with R/R acute lymphoblastic leukemia (ALL).
    Assi, Rita
    Kantarjian, Hagop M.
    Ravandi, Farhad
    O'Brien, Susan Mary
    Kebriaei, Partow
    Thomas, Deborah A.
    Garcia-Manero, Guillermo
    Khouri, Issa F.
    Champlin, Richard E.
    Kadia, Tapan M.
    Cortes, Jorge E.
    Jain, Nitin
    Konopleva, Marina
    Khouri, Rita
    Estrov, Zeev
    Takahashi, Koichi
    Sasaki, Koji
    Jacob, Jovitta
    Garris, Rebecca
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345